

Caryl E Sortwell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8412436/publications.pdf>

Version: 2024-02-01

53
papers

2,100
citations

257101

24
h-index

243296

44
g-index

66
all docs

66
docs citations

66
times ranked

2522
citing authors

#	ARTICLE	IF	CITATIONS
1	BDNF rs6265 Genotype Influences Outcomes of Pharmacotherapy and Subthalamic Nucleus Deep Brain Stimulation in Early-Stage Parkinson's Disease. <i>Neuromodulation</i> , 2022, 25, 846-853.	0.4	6
2	Behavioral phenotyping of a rat model of the BDNF Val66Met polymorphism reveals selective impairment of fear memory. <i>Translational Psychiatry</i> , 2022, 12, 93.	2.4	16
3	Dopaminergic Positron Emission Tomography Imaging in the Alpha-Synuclein Preformed Fibril Model Reveals Similarities to Early Parkinson's Disease. <i>Movement Disorders</i> , 2022, 37, 1739-1748.	2.2	8
4	Beta2-adrenoreceptor agonist clenbuterol produces transient decreases in alpha-synuclein mRNA but no long-term reduction in protein. <i>Npj Parkinson's Disease</i> , 2022, 8, .	2.5	6
5	Leveraging the preformed fibril model to distinguish between alpha-synuclein inclusion- and nigrostriatal degeneration-associated immunogenicity. <i>Neurobiology of Disease</i> , 2022, 171, 105804.	2.1	12
6	The BDNF Val66Met polymorphism (rs6265) enhances dopamine neuron graft efficacy and side-effect liability in rs6265 knock-in rats. <i>Neurobiology of Disease</i> , 2021, 148, 105175.	2.1	13
7	Striatal Afferent BDNF Is Disrupted by Synucleinopathy and Partially Restored by STN DBS. <i>Journal of Neuroscience</i> , 2021, 41, 2039-2052.	1.7	16
8	Stereotaxic Intracranial Delivery of Chemicals, Proteins or Viral Vectors to Study Parkinson's Disease. <i>Journal of Visualized Experiments</i> , 2021, , .	0.2	0
9	Î±-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson's disease. <i>JCI Insight</i> , 2021, 6, .	2.3	60
10	Synucleinopathy-associated pathogenesis in Parkinson's disease and the potential for brain-derived neurotrophic factor. <i>Npj Parkinson's Disease</i> , 2021, 7, 35.	2.5	26
11	Preformed fibrils generated from mouse alpha-synuclein produce more inclusion pathology in rats than fibrils generated from rat alpha-synuclein. <i>Parkinsonism and Related Disorders</i> , 2021, 89, 41-47.	1.1	7
12	Next-Generation Diamond Electrodes for Neurochemical Sensing: Challenges and Opportunities. <i>Micromachines</i> , 2021, 12, 128.	1.4	15
13	BDNF rs6265 Variant Alters Outcomes with Levodopa in Early-Stage Parkinson's Disease. <i>Neurotherapeutics</i> , 2020, 17, 1785-1795.	2.1	12
14	Striatal Nurr1, but not FosB expression links a levodopa-induced dyskinesia phenotype to genotype in Fisher 344 vs. Lewis hemiparkinsonian rats. <i>Experimental Neurology</i> , 2020, 330, 113327.	2.0	10
15	Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease. <i>Journal of Neuroscience</i> , 2020, 40, 3675-3691.	1.7	15
16	Developmental exposure to the organochlorine pesticide dieldrin causes male-specific exacerbation of Î±-synuclein-preformed fibril-induced toxicity and motor deficits. <i>Neurobiology of Disease</i> , 2020, 141, 104947.	2.1	24
17	Time course and magnitude of alpha-synuclein inclusion formation and nigrostriatal degeneration in the rat model of synucleinopathy triggered by intrastratial Î±-synuclein preformed fibrils. <i>Neurobiology of Disease</i> , 2019, 130, 104525.	2.1	67
18	Generation of Alpha-Synuclein Preformed Fibrils from Monomers and Use In Vivo. <i>Journal of Visualized Experiments</i> , 2019, , .	0.2	29

#	ARTICLE	IF	CITATIONS
19	Genetic silencing of striatal CaV1.3 prevents and ameliorates levodopa dyskinesia. <i>Movement Disorders</i> , 2019, 34, 697-707.	2.2	19
20	BDNF provides many routes toward STN DBS-mediated disease modification. <i>Movement Disorders</i> , 2019, 34, 22-34.	2.2	20
21	Impact of the Aged Brain Environment on Gene Therapy for Parkinson's Disease. , 2018, , 647-657.		0
22	Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration. <i>Journal of Neuroinflammation</i> , 2018, 15, 129.	3.1	131
23	Quality Over Quantity: Advantages of Using Alpha-Synuclein Preformed Fibril Triggered Synucleinopathy to Model Idiopathic Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2018, 12, 621.	1.4	32
24	Bdnf variant is associated with milder motor symptom severity in early-stage Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 53, 70-75.	1.1	13
25	Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson's Disease in Rodents. <i>Journal of Parkinson's Disease</i> , 2018, 8, 303-322.	1.5	151
26	Silencing Alpha Synuclein in Mature Nigral Neurons Results in Rapid Neuroinflammation and Subsequent Toxicity. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 36.	1.4	75
27	Glycomic and Proteomic Changes in Aging Brain Nigrostriatal Pathway. <i>Molecular and Cellular Proteomics</i> , 2018, 17, 1778-1787.	2.5	27
28	Alpha-Synuclein mRNA Is Not Increased in Sporadic PD and Alpha-Synuclein Accumulation Does Not Block GDNF Signaling in Parkinson's Disease and Disease Models. <i>Molecular Therapy</i> , 2017, 25, 2231-2235.	3.7	49
29	Rationally Engineered AAV Capsids Improve Transduction and Volumetric Spread in the CNS. <i>Molecular Therapy - Nucleic Acids</i> , 2017, 8, 184-197.	2.3	48
30	Subthalamic Nucleus Deep Brain Stimulation Employs trkB Signaling for Neuroprotection and Functional Restoration. <i>Journal of Neuroscience</i> , 2017, 37, 6786-6796.	1.7	41
31	Can STN DBS protect both nigral somata and innervation of the striatum?. <i>Annals of Neurology</i> , 2017, 82, 855-855.	2.8	1
32	Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form. <i>Neurobiology of Disease</i> , 2017, 106, 191-204.	2.1	28
33	Subthalamic Nucleus Deep Brain Stimulation Does Not Modify the Functional Deficits or Axonopathy Induced by Nigrostriatal α -Synuclein Overexpression. <i>Scientific Reports</i> , 2017, 7, 16356.	1.6	24
34	Impact of age and vector construct on striatal and nigral transgene expression. <i>Molecular Therapy - Methods and Clinical Development</i> , 2016, 3, 16082.	1.8	21
35	Viral Vector-Based Modeling of Neurodegenerative Disorders: Parkinson's Disease. <i>Methods in Molecular Biology</i> , 2016, 1382, 367-382.	0.4	19
36	The Longitudinal Transcriptomic Response of the Substantia Nigra to Intrastratial 6-Hydroxydopamine Reveals Significant Upregulation of Regeneration-Associated Genes. <i>PLoS ONE</i> , 2015, 10, e0127768.	1.1	18

#	ARTICLE	IF	CITATIONS
37	Loss of VGLUT3 Produces Circadian-Dependent Hyperdopaminergia and Ameliorates Motor Dysfunction and l-Dopa-Mediated Dyskinesias in a Model of Parkinson's Disease. <i>Journal of Neuroscience</i> , 2015, 35, 14983-14999.	1.7	53
38	Recombinant adenoassociated virus 2/5-mediated gene transfer is reduced in the aged rat midbrain. <i>Neurobiology of Aging</i> , 2015, 36, 1110-1120.	1.5	22
39	Tricyclic antidepressant treatment evokes regional changes in neurotrophic factors over time within the intact and degenerating nigrostriatal system. <i>Experimental Neurology</i> , 2015, 266, 11-21.	2.0	22
40	Intrastratial injection of pre-formed mouse α -synuclein fibrils into rats triggers α -synuclein pathology and bilateral nigrostriatal degeneration. <i>Neurobiology of Disease</i> , 2015, 82, 185-199.	2.1	285
41	Interrogating the aged striatum: Robust survival of grafted dopamine neurons in aging rats produces inferior behavioral recovery and evidence of impaired integration. <i>Neurobiology of Disease</i> , 2015, 77, 191-203.	2.1	24
42	Chronic Amitriptyline Treatment Attenuates Nigrostriatal Degeneration and Significantly Alters Trophic Support in a Rat Model of Parkinsonism. <i>Neuropsychopharmacology</i> , 2015, 40, 874-883.	2.8	21
43	High-Frequency Stimulation of the Rat Entopeduncular Nucleus Does Not Provide Functional or Morphological Neuroprotection from 6-Hydroxydopamine. <i>PLoS ONE</i> , 2015, 10, e0133957.	1.1	14
44	Morphological and Behavioral Impact of AAV2/5-Mediated Overexpression of Human Wildtype Alpha-Synuclein in the Rat Nigrostriatal System. <i>PLoS ONE</i> , 2013, 8, e81426.	1.1	70
45	Striatal Pleiotrophin Overexpression Provides Functional and Morphological Neuroprotection in the 6-Hydroxydopamine Model. <i>Molecular Therapy</i> , 2012, 20, 544-554.	3.7	27
46	Endogenous neural precursors influence grafted neural stem cells and contribute to neuroprotection in the parkinsonian rat. <i>European Journal of Neuroscience</i> , 2012, 35, 883-895.	1.2	17
47	Subthalamic Nucleus Stimulation Increases Brain Derived Neurotrophic Factor in the Nigrostriatal System and Primary Motor Cortex. <i>Journal of Parkinson's Disease</i> , 2011, 1, 123-136.	1.5	64
48	Subthalamic nucleus stimulation increases brain derived neurotrophic factor in the nigrostriatal system and primary motor cortex. <i>Journal of Parkinson's Disease</i> , 2011, 1, 123-36.	1.5	44
49	Impact of dendritic spine preservation in medium spiny neurons on dopamine graft efficacy and the expression of dyskinesias in parkinsonian rats. <i>European Journal of Neuroscience</i> , 2010, 31, 478-490.	1.2	54
50	Focal not widespread grafts induce novel dyskinetic behavior in parkinsonian rats. <i>Neurobiology of Disease</i> , 2006, 21, 165-180.	2.1	93
51	Diminished Survival of Mesencephalic Dopamine Neurons Grafted into Aged Hosts Occurs during the Immediate Postgrafting Interval. <i>Experimental Neurology</i> , 2001, 169, 23-29.	2.0	62
52	Diminished Viability, Growth, and Behavioral Efficacy of Fetal Dopamine Neuron Grafts in Aging Rats with Long-Term Dopamine Depletion: An Argument for Neurotrophic Supplementation. <i>Journal of Neuroscience</i> , 1999, 19, 5563-5573.	1.7	83
53	Therapeutic Potential of Nerve Growth Factors in Parkinson's Disease. <i>Drugs and Aging</i> , 1999, 14, 261-287.	1.3	74